This segment focuses on the research and development of stem cell applications, particularly in regenerative medicine. VitaSpring Biomedical Co. Ltd. is actively investing in research to understand the mechanisms of human placenta and develop novel therapies. The company leverages its expertise in placenta mesenchymal stem cells and exosomes. This includes preclinical studies and clinical trials to evaluate the efficacy and safety of stem cell-based treatments. The segment aims to address unmet medical needs in areas such as tissue repair and organ regeneration, potentially impacting patients with chronic diseases and injuries. Market positioning involves establishing a leadership position in placenta stem cells. Future opportunities include expanding the product pipeline and securing strategic partnerships for clinical development and commercialization. Regulatory aspects involve navigating FDA approval processes and ensuring compliance with relevant guidelines.